Análisis coste-utilidad de dos formulaciones de toxina botulínica de tipo A en el tratamiento del blefaroespasmo y la distonía cervical en España

Sanz-Granda, Ángel; Martí, María José; Catalán, María José.
Rev. neurol. (Ed. impr.) ; 67(12): 465-472, 16 dic., 2018. graf, tab
Artículo en Español | IBECS (España) | ID: ibc-175176

Documentos relacionados

  1. [Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain].
  2. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
  3. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
  4. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.
  5. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
  6. Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial.
  7. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
  8. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
  9. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.
  10. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.